医学
恶性肿瘤
肝细胞癌
免疫疗法
肿瘤科
新辅助治疗
内科学
放射治疗
靶向治疗
癌症
乳腺癌
作者
Yanan Ma,Xuemei Jiang,Peipei Song,Wei Tang
出处
期刊:BioScience Trends
[International Research and Cooperation Association for Bio & Socio-Sciences Advancement]
日期:2024-02-29
卷期号:18 (1): 21-41
标识
DOI:10.5582/bst.2023.01436
摘要
Hepatocellular carcinoma (HCC), a challenging malignancy, often necessitates surgical intervention, notably liver resection. However, the high recurrence rate, reaching 70% within 5 years post-resection, significantly impacts patient outcomes. Neoadjuvant therapies aim to preoperatively address this challenge, reducing lesion size, improving surgical resection rates, deactivating potential micro-metastases, and ultimately lowering postoperative recurrence rates. This review concentrates on advances in research on and clinical use of neoadjuvant therapies for HCC, with particular attention to the use of immune checkpoint inhibitors (ICIs) targeting programmed cell death-1 (PD-1), programmed cell death ligand-1 (PD-L1), and cytotoxic T-lymphocyte-associated protein-4 (CTLA-4). Ongoing clinical studies exploring immunotherapy combined with a tyrosine kinase inhibitor (TKI), interventional therapy, radiotherapy, and other modalities offer promising insights into overcoming resistance to monotherapies. In summary, neoadjuvant therapies hold significant promise in terms of improving the prognosis for patients with HCC and enhancing long-term survival, particularly through innovative combination strategies.
科研通智能强力驱动
Strongly Powered by AbleSci AI